AJAaron Michael Johnston

Aaron Michael Johnston

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aaron Michael Johnston has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Antonios Kourliouros

    Cardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK

    3 shared publications
  • Chi Him Kendrick Yiu

    Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital, Oxford, UK

    3 shared publications
  • Kathryn Cox

    Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital, Oxford, UK

    3 shared publications
  • Rana Sayeed

    Cardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK

    3 shared publications
  • Svetlana Reilly

    Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital, Oxford, UK

    3 shared publications
  • Vivek Srivastava

    Cardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK

    3 shared publications

Latest Publications

  • Open Access

    Selective blockade of microRNA-31-5p−calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia burden

    by Jasha Trompf, Kathryn Cox, Mohit Hulsurkar, Lucia M. Moreira, Chi Him Kendrick Yiu, Aaron M. Johnston, Satadru K. Lahiri, Shuai Zhao, Paul Robinson, Roddy Hiram, et al.

    Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is promoted by atrial fibrosis, a form of structural remodelling for which effective therapies are lacking. MicroRNA-31-5p (miR-31-5p), an aging-associated, atrial-enriched microRNA, has been linked to AF, but its role in atrial fibrosis is unknown. Here we show that atrial fibroblasts from patients with persistent AF exhibit increased miR-31-5p expression and reduced expression of the calcitonin receptor (CTR, encoded by CALCR ). MiR-31-5p directly represses CTR and promotes pro-fibrotic fibroblast responses, whereas its inhibition restores CTR expression. Fibroblast-specific overexpression of miR-31 in mice reduces atrial CTR expression, increases atrial fibrosis and enhances arrhythmia susceptibility. Selective disruption of miR-31-5p− CALCR binding using a locked nucleic acid target site blocker restores atrial CTR expression, prevents fibrosis progression and reduces arrhythmia burden. In mice with established atrial remodeling, this strategy promotes fibrosis regression, identifying the miR-31-5p−CTR axis as a potential therapeutic target in AF.

  • Open Access

    Integrated Cardiac and Circulating N-glycan Signatures Reflect Atrial Remodeling in Patients with Atrial Fibrillation

    by Chi Him Kendrick Yiu, Jack Cheeseman, Georgia Elgood-Hunt, Chenhan Sam Ma, Abhirup Banerjee, Lucia M. Moreira, Aaron Michael Johnston, Neelam Mehta, Kathryn Cox, Timothy R. Betts, et al.

    Background: Atrial adverse remodeling drives the maintenance and progression of atrial fibrillation (AF) through electrical and structural myocardial changes, often accompanied by inflammation. Circulating N-glycans are emerging as biomarkers in inflammatory diseases, yet their role in AF remains undefined. Methods: We profiled the serum N-glycome of 138 patients with AF, non-AF arrhythmias, or sinus rhythm (SR) controls from peripheral venous (PV) and coronary sinus (CS) samples using hydrophilic interaction liquid chromatography coupled with high-resolution mass spectrometry. Glycan traits associated with AF were identified via logistic regression adjusted for clinical risk factors. Multivariate glycan scores were derived from PV and CS datasets using LASSO regression. In a subset (N=37), plasma proteome profiling was performed with the Olink Reveal panel. Results: Sixty-two glycan peaks were detected; 27 in PV and 8 in CS serum differed significantly between AF and controls. PV and CS glycan scores accurately classified AF, with the PV score correlating with 11 plasma proteins linked to structural remodeling and thrombo-inflammatory processes. The most abundant glycan, A2G2S2 (peak 30), was associated with higher odds of AF after adjusting for confounders (OR 2.22 [95% CI: 1.40–3.75], P = 0.001). CS A2G2S2 correlated with C-reactive protein (R = 0.432, P = 0.0275) and was elevated in patients with left atrial enlargement (P = 0.0354), but unchanged in those with impaired left ventricular ejection fraction or hypertrophy. Conclusion: Integrated profiling of peripheral and cardiac serum identifies novel N-glycosylation signatures in AF. Specific cardiac and circulating N-glycan signatures, including A2G2S2, are associated with AF and reflect inflammation-driven atrial remodeling, highlighting potential mechanistic pathways and biomarker applications.

  • Open Access

    Selective blockade of microRNA-31-5p/calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia substrate

    by Jasha Trompf, Kathryn Cox, Mohit Hulsurkar, Lucia M. Moreira, Chi Him Kendrick Yiu, Aaron M. Johnston, Satadru K. Lahiri, Shuai Zhao, Paul Robinson, Roddy Hiram, et al.

    Atrial fibrillation (AF), the commonest cardiac arrhythmia, is a major contributor to mortality and morbidity. Atrial tissue fibrosis, a hallmark of structural remodelling in AF, is currently incurable and significantly hinders AF-treatment. MicroRNA(miR)-31 is linked to ageing (a key risk factor for AF). Here, we show that AF-patients are characterised by upregulation of miR-31-5p in atrial cardiofibroblasts that negatively regulates the calcitonin receptor (CTR), thereby promoting atrial fibrogenesis and arrhythmia. Specific blockade of miR-31-5p/CTR-mRNA binding with LNA-miRNA-Target-Site-Blocker selectively increases atrial CTR expression and reverses advanced atrial fibrosis and arrhythmogenesis in vivo. These findings suggest a key role for miR-31-5p/CTR binding in promoting atrial fibrosis and arrhythmogenesis, and represents a first example of an RNA-based therapeutic capable of reversing established fibrosis that forms an AF substrate. *Jasha Trompf, Kathryn Cox, and Mohit Hulsurkar contributed equally to this work.